Clinical Trial Results:
A Multicenter Open-Label Study of Etanercept Withdrawal and Retreatment in Subjects With Non-Radiographic Axial Spondyloarthritis who Achieved Adequate 24 Week Response
Summary
|
|
EudraCT number |
2015-000541-24 |
Trial protocol |
DE FI BE PL HU SE ES NL CZ |
Global end of trial date |
06 Sep 2019
|
Results information
|
|
Results version number |
v1 |
This version publication date |
23 May 2020
|
First version publication date |
23 May 2020
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
B1801381
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Pfizer Inc.
|
||
Sponsor organisation address |
235 E 42nd Street, New York, United States, NY 10017
|
||
Public contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Scientific contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
21 Feb 2020
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
06 Sep 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To estimate the proportion of subjects who flare within 40 weeks following withdrawal of ETN in subjects who have achieved ASDAS CRP less than 1.3 (inactive disease)
|
||
Protection of trial subjects |
The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
24 Sep 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Australia: 27
|
||
Country: Number of subjects enrolled |
Belgium: 5
|
||
Country: Number of subjects enrolled |
Colombia: 7
|
||
Country: Number of subjects enrolled |
Czech Republic: 17
|
||
Country: Number of subjects enrolled |
Finland: 9
|
||
Country: Number of subjects enrolled |
France: 2
|
||
Country: Number of subjects enrolled |
Germany: 14
|
||
Country: Number of subjects enrolled |
Hungary: 5
|
||
Country: Number of subjects enrolled |
Netherlands: 4
|
||
Country: Number of subjects enrolled |
Poland: 75
|
||
Country: Number of subjects enrolled |
Spain: 11
|
||
Country: Number of subjects enrolled |
Sweden: 7
|
||
Country: Number of subjects enrolled |
Taiwan: 13
|
||
Country: Number of subjects enrolled |
United States: 13
|
||
Worldwide total number of subjects |
209
|
||
EEA total number of subjects |
149
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
209
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||
Recruitment details |
The study was conducted in the 14 countries from 24 September 2015 to 20 September 2019. A total of 210 subjects were enrolled. | ||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||
Screening details |
The first visit of the Period 3 (re-treatment period) might occur at the same time as a regularly scheduled visit during Period 2 (withdrawal period) or as an unscheduled visit for a subject who experienced flare during Period 2. | ||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||
Period 1 title |
Induction Period (24 weeks)
|
||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||
Arm title
|
Etanercept | ||||||||||||||||||||||
Arm description |
All enrolled subjects with non-radiographic axial spondyloarthritis (nr-ax SpA) were treated for 24 weeks with 50-milligram (mg) weekly dose of Etanercept in Period 1 (Induction Period). Subjects who achieved ankylosing spondylitis disease activity scale(ASDAS) C-reactive protein (CRP) less than (<) 1.3 at Week 24 entered into Period 2 (Withdrawal Period). In this period, subjects discontinued Etanercept for 40 weeks and subjects who achieved an ASDAS erythrocyte sedimentation rate (ESR) level greater than or equal to (>=) 2.1 by Week 64, then entered into Period 3 (Retreatment Period) of 12 weeks, treated with 50 mg weekly doses, and then followed up until 28 days after last dose of Etanercept. Subjects who did not qualify for Period 2 or 3 were followed up until 28 days after last dose of Etanercept. | ||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||
Investigational medicinal product name |
Etanercept
|
||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||
Other name |
|||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||
Dosage and administration details |
Subjects received Etanercept 50 mg weekly dose for 24 weeks.
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||
Period 2 title |
Withdrawal Period (40 weeks)
|
||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||
Arm title
|
Etanercept | ||||||||||||||||||||||
Arm description |
All enrolled subjects with non-radiographic axial spondyloarthritis (nr-ax SpA) were treated for 24 weeks with 50-milligram (mg) weekly dose of Etanercept in Period 1 (Induction Period). Subjects who achieved ankylosing spondylitis disease activity scale(ASDAS) C-reactive protein (CRP) less than (<) 1.3 at Week 24 entered into Period 2 (Withdrawal Period). In this period, subjects discontinued Etanercept for 40 weeks and subjects who achieved an ASDAS erythrocyte sedimentation rate (ESR) level greater than or equal to (>=) 2.1 by Week 64, then entered into Period 3 (Retreatment Period) of 12 weeks, treated with 50 mg weekly doses, and then followed up until 28 days after last dose of Etanercept. Subjects who did not qualify for Period 2 or 3 were followed up until 28 days after last dose of Etanercept. | ||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||
Investigational medicinal product name |
Etanercept
|
||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||
Other name |
|||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||
Dosage and administration details |
Subjects discontinued Etanercept in Period 2.
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
Notes [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: Participants who completed Period 1 and achieved ASDAS-CRP<1.3 were eligible to enter into Period 2. Participants who completed Period 2 and achieved ASDAS-ESR>=2.1 were eligible to enter into Period 3. |
|||||||||||||||||||||||
Period 3
|
|||||||||||||||||||||||
Period 3 title |
Retreatment Period (12 weeks)
|
||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||
Arm title
|
Etanercept | ||||||||||||||||||||||
Arm description |
All enrolled subjects with non-radiographic axial spondyloarthritis (nr-ax SpA) were treated for 24 weeks with 50-milligram (mg) weekly dose of Etanercept in Period 1 (Induction Period). Subjects who achieved ankylosing spondylitis disease activity scale(ASDAS) C-reactive protein (CRP) less than (<) 1.3 at Week 24 entered into Period 2 (Withdrawal Period). In this period, subjects discontinued Etanercept for 40 weeks and subjects who achieved an ASDAS erythrocyte sedimentation rate (ESR) level greater than or equal to (>=) 2.1 by Week 64, then entered into Period 3 (Retreatment Period) of 12 weeks, treated with 50 mg weekly doses, and then followed up until 28 days after last dose of Etanercept. Subjects who did not qualify for Period 2 or 3 were followed up until 28 days after last dose of Etanercept. | ||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||
Investigational medicinal product name |
Etanercept
|
||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||
Other name |
|||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||
Dosage and administration details |
Subjects received Etanercept 50 mg weekly dose for 12 weeks.
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
Notes [2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: Participants who completed Period 1 and achieved ASDAS-CRP<1.3 were eligible to enter into Period 2. Participants who completed Period 2 and achieved ASDAS-ESR>=2.1 were eligible to enter into Period 3. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Etanercept
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All enrolled subjects with non-radiographic axial spondyloarthritis (nr-ax SpA) were treated for 24 weeks with 50-milligram (mg) weekly dose of Etanercept in Period 1 (Induction Period). Subjects who achieved ankylosing spondylitis disease activity scale(ASDAS) C-reactive protein (CRP) less than (<) 1.3 at Week 24 entered into Period 2 (Withdrawal Period). In this period, subjects discontinued Etanercept for 40 weeks and subjects who achieved an ASDAS erythrocyte sedimentation rate (ESR) level greater than or equal to (>=) 2.1 by Week 64, then entered into Period 3 (Retreatment Period) of 12 weeks, treated with 50 mg weekly doses, and then followed up until 28 days after last dose of Etanercept. Subjects who did not qualify for Period 2 or 3 were followed up until 28 days after last dose of Etanercept. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Etanercept
|
||
Reporting group description |
All enrolled subjects with non-radiographic axial spondyloarthritis (nr-ax SpA) were treated for 24 weeks with 50-milligram (mg) weekly dose of Etanercept in Period 1 (Induction Period). Subjects who achieved ankylosing spondylitis disease activity scale(ASDAS) C-reactive protein (CRP) less than (<) 1.3 at Week 24 entered into Period 2 (Withdrawal Period). In this period, subjects discontinued Etanercept for 40 weeks and subjects who achieved an ASDAS erythrocyte sedimentation rate (ESR) level greater than or equal to (>=) 2.1 by Week 64, then entered into Period 3 (Retreatment Period) of 12 weeks, treated with 50 mg weekly doses, and then followed up until 28 days after last dose of Etanercept. Subjects who did not qualify for Period 2 or 3 were followed up until 28 days after last dose of Etanercept. | ||
Reporting group title |
Etanercept
|
||
Reporting group description |
All enrolled subjects with non-radiographic axial spondyloarthritis (nr-ax SpA) were treated for 24 weeks with 50-milligram (mg) weekly dose of Etanercept in Period 1 (Induction Period). Subjects who achieved ankylosing spondylitis disease activity scale(ASDAS) C-reactive protein (CRP) less than (<) 1.3 at Week 24 entered into Period 2 (Withdrawal Period). In this period, subjects discontinued Etanercept for 40 weeks and subjects who achieved an ASDAS erythrocyte sedimentation rate (ESR) level greater than or equal to (>=) 2.1 by Week 64, then entered into Period 3 (Retreatment Period) of 12 weeks, treated with 50 mg weekly doses, and then followed up until 28 days after last dose of Etanercept. Subjects who did not qualify for Period 2 or 3 were followed up until 28 days after last dose of Etanercept. | ||
Reporting group title |
Etanercept
|
||
Reporting group description |
All enrolled subjects with non-radiographic axial spondyloarthritis (nr-ax SpA) were treated for 24 weeks with 50-milligram (mg) weekly dose of Etanercept in Period 1 (Induction Period). Subjects who achieved ankylosing spondylitis disease activity scale(ASDAS) C-reactive protein (CRP) less than (<) 1.3 at Week 24 entered into Period 2 (Withdrawal Period). In this period, subjects discontinued Etanercept for 40 weeks and subjects who achieved an ASDAS erythrocyte sedimentation rate (ESR) level greater than or equal to (>=) 2.1 by Week 64, then entered into Period 3 (Retreatment Period) of 12 weeks, treated with 50 mg weekly doses, and then followed up until 28 days after last dose of Etanercept. Subjects who did not qualify for Period 2 or 3 were followed up until 28 days after last dose of Etanercept. | ||
Subject analysis set title |
Etanercept: Period 1
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
All enrolled subjects with nr-ax SpA were treated for 24 weeks with 50 milligram weekly dose of Etanercept in Period 1 (Induction Period). Subjects who did not qualify for Period 2 were followed up until 28 days after last dose of Etanercept.
|
||
Subject analysis set title |
Etanercept: Period 2
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Subjects who achieved ASDAS CRP less than 1.3 at Week 24 then entered into Period 2 (Withdrawal Period). In this period, subjects discontinued Etanercept for 40 weeks (from Week 24 to Week 64). Subjects who did not qualify for Period 2 were followed up until 28 days after last dose of Etanercept.
|
||
Subject analysis set title |
Etanercept: Period 3
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Subjects who achieved an ASDAS ESR level >= 2.1 by Week 64, then entered into Period 3 (Retreatment Period) of 12 weeks, treated with 50 mg weekly doses, and then followed up until 28 days after last dose of Etanercept.
|
|
|||||||||
End point title |
Percentage of Subjects Who Experienced Flare Within 40 Weeks Following Withdrawal of 24 Weeks of Etanercept Treatment [1] | ||||||||
End point description |
Subjects who experienced ASDAS-Erythrocyte Sedimentation Rate (ESR) level of >=2.1 were defined as being flared. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0 = no disease activity and 10= high disease activity. CRP measured in milligram per liter (mg/L) and ESR measured in millimeter per hour (mm/hr). Percentage of subjects who flared within 40 weeks after the withdrawal of Etanercept treatment of 24 weeks in Induction period are reported in this outcome measure. Full analysis set for period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed last observation carried forward (LOCF).
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Within 40 weeks after Etanercept withdrawal (from Week 24 to Week 64)
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive data was planned to be analysed for this endpoint |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Time to Flare Following Withdrawal of Etanercept Treatment | ||||||||
End point description |
Subjects who experienced ASDAS-ESR level of >=2.1 were defined as being flared. Time to experience flare in subjects was defined as time to achieve ASDAS-ESR level of >=2.1 after the withdrawal of Etanercept treatment of 24 weeks in Induction period. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0 = no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. Full analysis set for period 2 included all subjects who had at least one evaluation during period 2.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Within 40 weeks after Etanercept withdrawal (from Week 24 to Week 64)
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Less Than (<)1.3: Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS ranged as inactive disease: 0 <= ASDAS-CRP <1.3; moderate disease activity: 1.3 <= ASDAS-CRP <2.1; high disease activity: 2.1 <= ASDAS-CRP <=3.5; very high disease activity: 3.5 < ASDAS-CRP. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Less Than (<)1.3: Observed Cases (OC): Period 2 | ||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS ranged as inactive disease: 0 <= ASDAS-CRP <1.3; moderate disease activity: 1.3 <= ASDAS-CRP <2.1; high disease activity: 2.1 <= ASDAS-CRP <=3.5; very high disease activity: 3.5 < ASDAS-CRP. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Less Than (<)1.3: Observed Cases (OC): Period 3 | ||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS ranged as inactive disease: 0 <= ASDAS-CRP <1.3; moderate disease activity: 1.3 <= ASDAS-CRP <2.1; high disease activity: 2.1 <= ASDAS-CRP <=3.5; very high disease activity: 3.5 < ASDAS-CRP. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Week 68, 72, 76
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Less Than (<) 1.3: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS ranged as inactive disease: 0 <= ASDAS-CRP <1.3; moderate disease activity: 1.3 <= ASDAS-CRP <2.1; high disease activity: 2.1 <= ASDAS-CRP <=3.5; very high disease activity: 3.5 < ASDAS-CRP. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Less Than (<) 1.3: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS ranged as inactive disease: 0 <= ASDAS-CRP <1.3; moderate disease activity: 1.3 <= ASDAS-CRP <2.1; high disease activity: 2.1 <= ASDAS-CRP <=3.5; very high disease activity: 3.5 < ASDAS-CRP. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Less Than (<) 1.3: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS ranged as inactive disease: 0 <= ASDAS-CRP <1.3; moderate disease activity: 1.3 <= ASDAS-CRP <2.1; high disease activity: 2.1 <= ASDAS-CRP <=3.5; very high disease activity: 3.5 < ASDAS-CRP Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Week 68, 72, 76
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS 20) Response: Observed Cases (OC): Period 1 | ||||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function (from [Bath Ankylosing Spondylitis Functional Index] BASFI) and inflammation (from [Bath Ankylosing Spondylitis Disease Activity Index] BASDAI). ASAS 20 responders: subjects with at least 20% improvement from baseline in disease activity and an absolute change of at least 1 unit on a 0 to 10 cm scale (0=no disease activity; 10=high disease activity, where higher scores indicated higher disease activity) in 3 or more domains, and no worsening of >=20% and absolute change 1 unit in the remaining domain. All 4 domains were measured on a 0-100 mm scale (0= no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 20. FAS for Period 1 analysed. Here, “n” = subjects evaluable at specific time points.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS 20) Response: Observed Cases (OC): Period 2 | ||||||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). ASAS 20 responders were defined as subjects with at least 20% improvement from baseline in disease activity and an absolute change of at least 1 unit on a 0 to 10 cm scale (0=no disease activity; 10=high disease activity, where higher scores indicated higher disease activity) in 3 or more domains, and no worsening of >=20% and absolute change 1 unit in the remaining domain. All 4 domains were measured on a 0-100 millimeter (mm) scale (0= no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 20. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS 20) Response: Observed Cases (OC): Period 3 | ||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). ASAS 20 responders were defined as subjects with at least 20% improvement from baseline in disease activity and an absolute change of at least 1 unit on a 0 to 10 cm scale (0=no disease activity; 10=high disease activity, where higher scores indicated higher disease activity) in 3 or more domains, and no worsening of >=20% and absolute change 1 unit in the remaining domain. All 4 domains were measured on a 0-100 millimeter (mm) scale (0= no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 20. Full analysis set analyzed. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS 20) Response: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). ASAS 20 responders: subjects with at least 20% improvement from baseline in disease activity and an absolute change of at least 1 unit on a 0 to 10 cm scale (0=no disease activity; 10=high disease activity, where higher scores indicated higher disease activity) in 3 or more domains, and no worsening of >=20% and absolute change 1 unit in the remaining domain. All 4 domains were measured on a 0-100 mm scale (0= no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 20. FAS for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS 20) Response: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). ASAS 20 responders: subjects with at least 20% improvement from baseline in disease activity and an absolute change of at least 1 unit on a 0 to 10 cm scale (0=no disease activity; 10=high disease activity, where higher scores indicated higher disease activity) in 3 or more domains, and no worsening of >=20% and absolute change 1 unit in the remaining domain. All 4 domains were measured on a 0-100 mm scale (0= no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 20. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS 20) Response: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). ASAS 20 responders: subjects with at least 20% improvement from baseline in disease activity and an absolute change of at least 1 unit on a 0 to 10 cm scale (0=no disease activity; 10=high disease activity, where higher scores indicated higher disease activity) in 3 or more domains, and no worsening of >=20% and absolute change 1 unit in the remaining domain. All 4 domains measured on 0-100 mm scale (0= no disease activity; 100 = high disease activity, higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 20. FAS Period 3: all subjects who took study retreatment medication and had at least 1 evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society 40 (ASAS 40) Response: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). ASAS 40 responders: subjects with at least 40% and absolute improvement of at least 2 units on a 0 to 10 cm scale (converted from 0 to 100 mm) or an improvement of 100% for those domains that have a baseline score <2 in at least 3 of the 4 domains: subject assessment of disease activity, mean of subjects assessment of total back pain, function represented by the BASFI score, inflammation represented by the mean of the two morning stiffness-related BASDAI scores. No worsening at all in any of the domains. Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 40.FAS Period 1 population. Missing data was imputed using mixed LOCF.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society 40 (ASAS 40) Response: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function. ASAS 40 responders: subjects with at least 40% and absolute improvement of at least 2 units on a 0 to 10 cm scale (converted from 0 to 100 mm) or an improvement of 100% for those domains that have a baseline score <2 in at least 3 of the 4 domains: subject assessment of disease activity, mean of subjects assessment of total back pain, function represented by the BASFI score, inflammation represented by the mean of the two morning stiffness-related BASDAI scores. No worsening at all in any of the domains. Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 40.FAS Period 2 population. Missing data was imputed using mixed LOCF.“n” = subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society 40 (ASAS 40) Response: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function. ASAS 40 responders: subjects with at least 40% and absolute improvement of at least 2 units on a 0 to 10 cm scale (converted from 0 to 100 mm) or an improvement of 100% for those domains that have a baseline score <2 in at least 3 of the 4 domains: subject assessment of disease activity, mean of subjects assessment of total back pain, function represented by the BASFI score, inflammation represented by the mean of the two morning stiffness-related BASDAI scores. No worsening at all in any of the domains. Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 40.FAS Period 3 population. Missing data was imputed using mixed LOCF. “n” = subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society 40 (ASAS 40) Response: Observed Cases (OC): Period 1 | ||||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function. ASAS 40 responders: subjects with at least 40% and absolute improvement of at least 2 units on a 0 to 10 cm scale (converted from 0 to 100 mm) or an improvement of 100% for those domains that have a baseline score <2 in at least 3 of the 4 domains: subject assessment of disease activity, mean of subjects assessment of total back pain, function represented by the BASFI score, inflammation represented by the mean of the two morning stiffness-related BASDAI scores. No worsening at all in any of the domains. Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 40. FAS Period 1 population. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society 40 (ASAS 40) Response: Observed Cases (OC): Period 2 | ||||||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function. ASAS 40 responders: subjects with at least 40% and absolute improvement of at least 2 units on a 0 to 10 cm scale (converted from 0 to 100 mm) or an improvement of 100% for those domains that have a baseline score <2 in at least 3 of the 4 domains: subject assessment of disease activity, mean of subjects assessment of total back pain, function represented by the BASFI score, inflammation represented by the mean of the two morning stiffness-related BASDAI scores. No worsening at all in any of the domains. Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 40. FAS Period 2 population. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society 40 (ASAS 40) Response: Observed Cases (OC): Period 3 | ||||||||||||||||
End point description |
ASAS measures symptomatic improvement in AS in 4 domains: subject global assessment of disease activity, total back pain, function. ASAS 40 responders: subjects with at least 40% and absolute improvement of at least 2 units on a 0 to 10 cm scale (converted from 0 to 100 mm) or an improvement of 100% for those domains that have a baseline score <2 in at least 3 of the 4 domains: subject assessment of disease activity, mean of subjects assessment of total back pain, function represented by the BASFI score, inflammation represented by the mean of the two morning stiffness-related BASDAI scores. No worsening at all in any of the domains. Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). These scores were then converted to 0-10 cm scale for assessment of ASAS 40. FAS Period 3 population. “n” = subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS) Partial Remission: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||
End point description |
ASAS partial remission was defined as a score of 2 units or less (on a scale of 0-10 cm, where 0 = no disease activity and 10 = high disease activity) in each of the 4 domains of ASAS: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). Reported values were then converted into cm for analysis. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS) Partial Remission: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||
End point description |
ASAS partial remission was defined as a score of 2 units or less (on a scale of 0-10 cm, where 0 = no disease activity and 10 = high disease activity) in each of the 4 domains of ASAS: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). Reported values were then converted into cm for analysis. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2.Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS) Partial Remission: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||
End point description |
ASAS partial remission was defined as a score of 2 units or less (on a scale of 0-10 cm, where 0 = no disease activity and 10 = high disease activity) in each of the 4 domains of ASAS: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). Reported values were then converted into cm for analysis. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS) Partial Remission: Observed Cases (OC): Period 1 | ||||||||||||||||||
End point description |
ASAS partial remission was defined as a score of 2 units or less (on a scale of 0-10 cm, where 0 = no disease activity and 10 = high disease activity) in each of the 4 domains of ASAS: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). Reported values were then converted into cm for analysis. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS) Partial Remission: Observed Cases (OC): Period 2 | ||||||||||||||||||||
End point description |
ASAS partial remission was defined as a score of 2 units or less (on a scale of 0-10 cm, where 0 = no disease activity and 10 = high disease activity) in each of the 4 domains of ASAS: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). Reported values were then converted into cm for analysis. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Assessment of Spondyloarthritis Society (ASAS) Partial Remission: Observed Cases (OC): Period 3 | ||||||||||||||||
End point description |
ASAS partial remission was defined as a score of 2 units or less (on a scale of 0-10 cm, where 0 = no disease activity and 10 = high disease activity) in each of the 4 domains of ASAS: subject global assessment of disease activity, total back pain, function (from BASFI) and inflammation (from BASDAI). Each domain was measured on a 0-100 mm scale (0=no disease activity; 100 = high disease activity, where higher scores indicated higher disease activity). Reported values were then converted into cm for analysis. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Score: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
ASDAS: score combining assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on VAS ranging 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS ranged as inactive disease: 0<= ASDAS-CRP <1.3; moderate disease activity: 1.3<= ASDAS-CRP <2.1; high disease activity: 2.1<= ASDAS-CRP <=3.5; very high disease activity: 3.5< ASDAS-CRP. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Score: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
ASDAS: score combining assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on VAS ranging 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS ranged as inactive disease: 0<= ASDAS-CRP <1.3; moderate disease activity: 1.3<= ASDAS-CRP <2.1; high disease activity: 2.1<= ASDAS-CRP <=3.5; very high disease activity: 3.5< ASDAS-CRP. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Score: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
ASDAS: score combining assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP/ESR assessed on VAS ranging 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L & ESR measured in mm/hr. ASDAS ranged as inactive disease: 0<= ASDAS-CRP <1.3; moderate disease activity: 1.3<= ASDAS-CRP <2.1; high disease activity: 2.1<= ASDAS-CRP <=3.5; very high disease activity: 3.5< ASDAS-CRP. ASDAS-CRP is calculated as: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 3 included all subjects who took study retreatment medication and
had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Score: Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
ASDAS: score combining assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP/ESR assessed on VAS ranging 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L & ESR measured in mm/hr. ASDAS ranged as inactive disease: 0<= ASDAS-CRP <1.3; moderate disease activity: 1.3<= ASDAS-CRP <2.1; high disease activity: 2.1<= ASDAS-CRP <=3.5; very high disease activity: 3.5< ASDAS-CRP. ASDAS-CRP is calculated as: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Score: Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
ASDAS: score combining assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP/ESR assessed on VAS ranging 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L & ESR measured in mm/hr. ASDAS ranged as inactive disease: 0<= ASDAS-CRP <1.3; moderate disease activity: 1.3<= ASDAS-CRP <2.1; high disease activity: 2.1<= ASDAS-CRP <=3.5; very high disease activity: 3.5< ASDAS-CRP. ASDAS-CRP is calculated as: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1: Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Score: Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
ASDAS: score combining assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP/ESR assessed on VAS ranging 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L & ESR measured in mm/hr. ASDAS ranged as inactive disease: 0<= ASDAS-CRP <1.3; moderate disease activity: 1.3<= ASDAS-CRP <2.1; high disease activity: 2.1<= ASDAS-CRP <=3.5; very high disease activity: 3.5< ASDAS-CRP. ASDAS-CRP is calculated as: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) Erythrocyte Sedimentation Rate (ESR) Score: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0 = no disease activity and 100= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS-ESR was calculated with the following equation: 0.8*total back pain+0.11*subject global+0.09*peripheral pain/swelling+0.07*duration of morning stiffness+ 0.29*ESR^1/2. ASDAS ranged as inactive disease: 0 <= ASDAS-ESR <1.3; active disease: 1.3 <= ASDAS-ESR =<2.1. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-Erythrocyte Sedimentation Rate (ESR) Score: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0 = no disease activity and 100= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS-ESR was calculated with the following equation: 0.8*total back pain+0.11*subject global+0.09*peripheral pain/swelling+0.07*duration of morning stiffness+ 0.29*ESR^1/2. ASDAS ranged as inactive disease: 0 <= ASDAS-ESR <1.3; active disease: 1.3 <= ASDAS-ESR =<2.1. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-Erythrocyte Sedimentation Rate (ESR) Score: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0 = no disease activity and 100= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS-ESR was calculated with the following equation: 0.8*total back pain+0.11*subject global+0.09*peripheral pain/swelling+0.07*duration of morning stiffness+ 0.29*ESR^1/2. ASDAS ranged as inactive disease: 0 <= ASDAS-ESR <1.3; active disease: 1.3 <= ASDAS-ESR =<2.1. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) Erythrocyte Sedimentation Rate (ESR) Score: Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0 = no disease activity and 100= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS-ESR was calculated with the following equation: 0.8*total back pain+0.11*subject global+0.09*peripheral pain/swelling+0.07*duration of morning stiffness+ 0.29*ESR^1/2. ASDAS ranged as inactive disease: 0 <= ASDAS-ESR <1.3; active disease: 1.3 <= ASDAS-ESR =<2.1. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-Erythrocyte Sedimentation Rate (ESR) Score: Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0 = no disease activity and 100= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS-ESR was calculated with the following equation: 0.8*total back pain+0.11*subject global+0.09*peripheral pain/swelling+0.07*duration of morning stiffness+ 0.29*ESR^1/2. ASDAS ranged as inactive disease: 0 <= ASDAS-ESR <1.3; active disease: 1.3 <= ASDAS-ESR =<2.1. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)-Erythrocyte Sedimentation Rate (ESR) Score: Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0 = no disease activity and 100= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. ASDAS-ESR was calculated with the following equation: 0.8*total back pain+0.11*subject global+0.09*peripheral pain/swelling+0.07*duration of morning stiffness+ 0.29*ESR^1/2. ASDAS ranged as inactive disease: 0 <= ASDAS-ESR <1.3; active disease: 1.3 <= ASDAS-ESR =<2.1. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Major Improvement: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||
End point description |
Major improvement in ASDAS-CRP was defined as decrease from baseline >= 2.0 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. FAS for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Major Improvement: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||
End point description |
Major improvement in ASDAS-CRP was defined as decrease from baseline >= 2.0 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Major Improvement: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||
End point description |
Major improvement in ASDAS-CRP was defined as decrease from baseline >= 2.0 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Major Improvement: Observed Cases (OC): Period 1 | ||||||||||||||||||
End point description |
Major improvement in ASDAS-CRP was defined as decrease from baseline >= 2.0 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Major Improvement: Observed Cases (OC): Period 2 | ||||||||||||||||||||
End point description |
Major improvement in ASDAS-CRP was defined as decrease from baseline >= 2.0 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110*subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln(CRP+1), Ln represents the natural logarithm. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Major Improvement: Observed Cases (OC): Period 3 | ||||||||||||||||
End point description |
ASDAS-CRP clinically important improvement was defined as a decrease from baseline of >=1.1 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110* subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln (CRP+1), Ln represents the natural logarithm. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Clinically Important Improvement: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||
End point description |
ASDAS-CRP clinically important improvement was defined as a decrease from baseline of >=1.1 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110* subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln (CRP+1), Ln represents the natural logarithm. FAS for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Clinically Important Improvement: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||
End point description |
ASDAS-CRP clinically important improvement was defined as a decrease from baseline of >=1.1 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110* subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln (CRP+1), Ln represents the natural logarithm. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Clinically Important Improvement: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||
End point description |
ASDAS-CRP clinically important improvement was defined as a decrease from baseline of >=1.1 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110* subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln (CRP+1), Ln represents the natural logarithm. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Clinically Important Improvement: Observed Cases (OC): Period 1 | ||||||||||||||||||
End point description |
ASDAS-CRP clinically important improvement was defined as a decrease from baseline of >=1.1 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110* subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln (CRP+1), Ln represents the natural logarithm. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Clinically Important Improvement: Observed Cases (OC): Period 2 | ||||||||||||||||||||
End point description |
ASDAS-CRP clinically important improvement was defined as a decrease from baseline of >=1.1 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110* subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln (CRP+1), Ln represents the natural logarithm. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Clinically Important Improvement: Observed Cases (OC): Period 3 | ||||||||||||||||
End point description |
ASDAS-CRP clinically important improvement was defined as a decrease from baseline of >=1.1 units. ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, subject global assessment of disease activity and CRP or ESR. All parameters other than CRP or ESR assessed on a VAS ranging from 0-10 cm, where 0= no disease activity and 10= high disease activity. CRP measured in mg/L and ESR measured in mm/hr. The ASDAS-CRP is calculated with the following equation: 0.121*total back pain+0.110* subject global+0.073*peripheral pain/swelling+0.058*duration of morning stiffness+0.579*Ln (CRP+1), Ln represents the natural logarithm.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Nocturnal Back Pain: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
Subjects assessed their nocturnal back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to centimeter (cm) for analysis. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Nocturnal Back Pain: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their nocturnal back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to centimeter (cm) for analysis. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Nocturnal Back Pain: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their nocturnal back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to centimeter (cm) for analysis. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Nocturnal Back Pain: Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
Subjects assessed their nocturnal back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to centimeter (cm) for analysis. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Nocturnal Back Pain: Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their nocturnal back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to centimeter (cm) for analysis. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Nocturnal Back Pain: Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their nocturnal back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to centimeter (cm) for analysis. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Total Back Pain: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
Subjects assessed their total back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to cm for analysis. Full analysis set for Period 1 included all sub who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Total Back Pain: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their total back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to cm for analysis. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Total Back Pain: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their total back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to cm for analysis. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Total Back Pain: Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
Subjects assessed their total back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to cm for analysis. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Total Back Pain: Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their total back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to cm for analysis. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Total Back Pain: Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their total back pain over the last 48 hours on a 100 mm VAS scale ranged from 0 mm (none) to 100 mm (severe), where higher scores indicated more pain. The reported values were converted to cm for analysis. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI): Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
BASFI is composed of 10 questions related to the subject’s ability to function. Each question scored by the subject on a 100 mm scale ranging from 0 (easy) to 100 (impossible), where higher scores indicated more difficulty in subject's ability to function. The BASFI total score calculated as mean of the scores for these 10 questions and converted to cm for analysis. BASFI total score was ranged from 0 (easy) to 10 (impossible), where higher scores indicated more difficulty in subject’s ability to function due to ankylosing spondylitis. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI): Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
BASFI is composed of 10 questions related to the subject’s ability to function. Each question scored by the subject on a 100 mm scale ranging from 0 (easy) to 100 (impossible), where higher scores indicated more difficulty in subject's ability to function. The BASFI total score calculated as mean of the scores for these 10 questions and converted to cm for analysis. BASFI total score was ranged from 0 (easy) to 10 (impossible), where higher scores indicated more difficulty in subject’s ability to function due to ankylosing spondylitis. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI): Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
BASFI is composed of 10 questions related to the subject’s ability to function. Each question scored by the subject on a 100 mm scale ranging from 0 (easy) to 100 (impossible), where higher scores indicated more difficulty in subject's ability to function. The BASFI total score calculated as mean of the scores for these 10 questions and converted to cm for analysis. BASFI total score was ranged from 0 (easy) to 10 (impossible), where higher scores indicated more difficulty in subject’s ability to function due to ankylosing spondylitis. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1: Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI): Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
BASFI is composed of 10 questions related to the subject’s ability to function. Each question scored by the subject on a 100 mm scale ranging from 0 (easy) to 100 (impossible), where higher scores indicated more difficulty in subject's ability to function. The BASFI total score calculated as mean of the scores for these 10 questions and converted to cm for analysis. BASFI total score was ranged from 0 (easy) to 10 (impossible), where higher scores indicated more difficulty in subject’s ability to function due to ankylosing spondylitis. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI): Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
BASFI is composed of 10 questions related to the subject’s ability to function. Each question scored by the subject on a 100 mm scale ranging from 0 (easy) to 100 (impossible), where higher scores indicated more difficulty in subject's ability to function. The BASFI total score calculated as mean of the scores for these 10 questions and converted to cm for analysis. BASFI total score was ranged from 0 (easy) to 10 (impossible), where higher scores indicated more difficulty in subject’s ability to function due to ankylosing spondylitis. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI): Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
BASFI is composed of 10 questions related to the subject’s ability to function. Each question scored by the subject on a 100 mm scale ranging from 0 (easy) to 100 (impossible), where higher scores indicated more difficulty in subject's ability to function. The BASFI total score calculated as mean of the scores for these 10 questions and converted to cm for analysis. BASFI total score was ranged from 0 (easy) to 10 (impossible), where higher scores indicated more difficulty in subject’s ability to function due to ankylosing spondylitis. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score: Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
BASDAI consisted of 6 questions related to disease activity. Each of first 5 questions was scored by subject on a 100 mm scale ranging from 0 (none) to 100 (very severe), where higher scores indicated more severe disease activity. Sixth question, related to duration of morning stiffness measured on a scale for 0 (0 hours) to 100 (2 hours), where higher scores indicated larger duration of morning stiffness. BASDAI score was obtained by computing mean score for the 2 questions related to morning stiffness (questions 5 [severity of morning stiffness] and 6 [duration of morning stiffness]) and then adding that value to sum of the scores for first 4 questions and then dividing the total by 5. This can be written as BASDAI=(Q1+Q2+Q3+Q4+(Q5+Q6)/2)/5.BASDAI total score ranged from 0 to 10, where higher scores indicated more severe disease activity. Reported values were converted to cm for analysis. FAS for Period 1 was analyzed. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score: Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
BASDAI consisted of 6 questions related to disease activity. Each of first 5 questions was scored by subject on a 100 mm scale ranging from 0 (none) to 100 (very severe), where higher scores indicated more severe disease activity. Sixth question, related to duration of morning stiffness measured on a scale for 0 (0 hours) to 100 (2 hours), where higher scores indicated larger duration of morning stiffness. BASDAI score was obtained by computing mean score for the 2 questions related to morning stiffness (questions 5 [severity of morning stiffness] and 6 [duration of morning stiffness]) and then adding that value to sum of the scores for first 4 questions and then dividing the total by 5. This can be written as BASDAI=(Q1+Q2+Q3+Q4+(Q5+Q6)/2)/5.BASDAI total score ranged from 0 to 10, where higher scores indicated more severe disease activity. Reported values were converted to cm for analysis. FAS for Period 2 was analyzed. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score: Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
BASDAI consisted of 6 questions related to disease activity. Each of first 5 questions was scored by subject on a 100 mm scale ranging from 0 (none) to 100 (very severe), where higher scores indicated more severe disease activity. Sixth question, related to duration of morning stiffness measured on a scale for 0 (0 hours) to 100 (2 hours), where higher scores indicated larger duration of morning stiffness. BASDAI score was obtained by computing mean score for the 2 questions related to morning stiffness (questions 5 [severity of morning stiffness] and 6 [duration of morning stiffness]) and then adding that value to sum of the scores for first 4 questions and then dividing the total by 5. This can be written as BASDAI=(Q1+Q2+Q3+Q4+(Q5+Q6)/2)/5.BASDAI total score ranged from 0 to 10, where higher scores indicated more severe disease activity. Reported values were converted to cm for analysis. FAS for Period 3 was analyzed. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1: Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
BASDAI: 6 questions related to disease activity. Each of first 5 questions was scored by subject on a 100 mm scale ranging from 0 (none) to 100 (very severe), where higher scores indicated more severe disease activity. Sixth question, related to duration of morning stiffness measured on a scale for 0 (0 hours) to 100 (2 hours), where higher scores indicated larger duration of morning stiffness. BASDAI score was obtained by computing mean score for the 2 questions related to morning stiffness (questions 5 [severity of morning stiffness] and 6 [duration of morning stiffness]) and then adding that value to sum of scores for first 4 questions and then dividing total by 5. BASDAI=(Q1+Q2+Q3+Q4+(Q5+Q6)/2)/5.BASDAI total score ranged from 0 to 10, where higher scores indicated more severe disease activity. Reported values were converted to cm for analysis. FAS for Period 1 was analyzed. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score:Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
BASDAI: 6 questions related to disease activity. Each of first 5 questions was scored by subject on a 100 mm scale ranging from 0 (none) to 100 (very severe), where higher scores indicated more severe disease activity. Sixth question, related to duration of morning stiffness measured on a scale for 0 (0 hours) to 100 (2 hours), where higher scores indicated larger duration of morning stiffness. BASDAI score was obtained by computing mean score for the 2 questions related to morning stiffness (questions 5 [severity of morning stiffness] and 6 [duration of morning stiffness]) and then adding that value to sum of scores for first 4 questions and then dividing total by 5. BASDAI=(Q1+Q2+Q3+Q4+(Q5+Q6)/2)/5.BASDAI total score ranged from 0 to 10, where higher scores indicated more severe disease activity. Reported values were converted to cm for analysis. FAS for Period 2 was analyzed. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
BASDAI: 6 questions related to disease activity. Each of first 5 questions was scored by subject on a 100 mm scale ranging from 0 (none) to 100 (very severe), where higher scores indicated more severe disease activity. Sixth question, related to duration of morning stiffness measured on a scale for 0 (0 hours) to 100 (2 hours), where higher scores indicated larger duration of morning stiffness. BASDAI score was obtained by computing mean score for the 2 questions related to morning stiffness (questions 5 [severity of morning stiffness] and 6 [duration of morning stiffness]) and then adding that value to sum of scores for first 4 questions and then dividing total by 5. BASDAI=(Q1+Q2+Q3+Q4+(Q5+Q6)/2)/5.BASDAI total score ranged from 0 to 10, where higher scores indicated more severe disease activity. Reported values were converted to cm for analysis. FAS for Period 3 was analyzed. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1: Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved at Least 50% Improvement From Baseline in Disease Activity According to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Observed Cases (OC): Period 1 | ||||||||||||||||||
End point description |
50% improvement from baseline in BASDAI: percentage of subjects achieved 50% decrease from baseline in BASDAI total score. BASDAI: 6 questions (Q) related to disease activity. Each of first 5 questions was scored by subject on 100 mm scale, range 0=none to 100=very severe, higher scores = more severe disease activity. Sixth question: duration of morning stiffness, was on scale for 0=0 hours to 100=2 hours, higher scores = larger duration of morning stiffness. BASDAI score obtained by computing mean score for 2 questions related to morning stiffness (Q5 [severity of morning stiffness], Q6 [duration of morning stiffness]) and adding that value to sum of scores for first 4Q and then dividing total by 5. BASDAI=(Q1+Q2+Q3+Q4+(Q5+Q6)/2)/5. BASDAI total score ranged from 0 to 10, higher scores = more severe disease activity. Reported values were converted to cm for analysis. Improvement was relative to baseline. FAS Period 1 was analyzed. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved at Least 50% Improvement From Baseline in Disease Activity According to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Observed Cases (OC): Period 2 | ||||||||||||||||||||
End point description |
50% improvement from baseline in BASDAI: percentage of subjects achieved 50% decrease from baseline in BASDAI total score. BASDAI: 6 questions (Q) related to disease activity. Each of first 5 questions was scored by subject on 100 mm scale, range 0=none to 100=very severe, higher scores = more severe disease activity. Sixth question: duration of morning stiffness, was on scale for 0=0 hours to 100=2 hours, higher scores = larger duration of morning stiffness. BASDAI score obtained by computing mean score for 2 questions related to morning stiffness (Q5 [severity of morning stiffness], Q6 [duration of morning stiffness]) and adding that value to sum of scores for first 4Q and then dividing total by 5. BASDAI=(Q1+Q2+Q3+Q4+(Q5+Q6)/2)/5. BASDAI total score ranged from 0 to 10, higher scores = more severe disease activity. Reported values were converted to cm for analysis. Improvement was relative to baseline. FAS Period 2 was analyzed. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Period 2 baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved at Least 50% Improvement From Baseline in Disease Activity According to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Observed Cases (OC): Period 3 | ||||||||||||||||
End point description |
50% improvement from baseline in BASDAI: percentage of subjects achieved 50% decrease from baseline in BASDAI total score. BASDAI: 6 questions (Q) related to disease activity. Each of first 5 questions was scored by subject on 100 mm scale, range 0=none to 100=very severe, higher scores = more severe disease activity. Sixth question: duration of morning stiffness, was on scale for 0=0 hours to 100=2 hours, higher scores = larger duration of morning stiffness. BASDAI score obtained by computing mean score for 2 questions related to morning stiffness (Q5 [severity of morning stiffness], Q6 [duration of morning stiffness]) and adding that value to sum of scores for first 4Q and then dividing total by 5. BASDAI=(Q1+Q2+Q3+Q4+(Q5+Q6)/2)/5. BASDAI total score ranged from 0 to 10, higher scores = more severe disease activity. Reported values were converted to cm for analysis. Improvement was relative to baseline. FAS Period 3 was analyzed. “n” = subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Period 3 baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved at Least 50% Improvement From Baseline in Disease Activity According to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) :Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||
End point description |
50% improvement from baseline in BASDAI: percentage of subjects achieved 50% decrease from baseline in BASDAI total score. BASDAI: 6 questions (Q) related to disease activity. Each of first 5 questions was scored by subject on 100 mm scale, range 0=none to 100=very severe, higher scores = more severe disease activity. Sixth question: duration of morning stiffness, was on scale for 0=0 hours to 100=2 hours, higher scores = larger duration of morning stiffness. BASDAI score obtained by computing mean score for 2 questions related to morning stiffness (Q5 [severity of morning stiffness], Q6 [duration of morning stiffness]) and adding that value to sum of scores for first 4Q and then dividing total by 5. Improvement was relative to baseline. FAS Period 1 was analyzed. Missing data was imputed using mixed LOCF.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved at Least 50% Improvement From Baseline in Disease Activity According to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) :Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||
End point description |
50% improvement from baseline in BASDAI: percentage of subjects achieved 50% decrease from baseline in BASDAI total score. BASDAI: 6 questions (Q) related to disease activity. Each of first 5 questions was scored by subject on 100 mm scale, range 0=none to 100=very severe, higher scores = more severe disease activity. Sixth question: duration of morning stiffness, was on scale for 0=0 hours to 100=2 hours, higher scores = larger duration of morning stiffness. BASDAI score obtained by computing mean score for 2 questions related to morning stiffness (Q5 [severity of morning stiffness], Q6 [duration of morning stiffness]) and adding that value to sum of scores for first 4Q and then dividing total by 5. Improvement was relative to baseline. FAS Period 2 was analyzed. Missing data was imputed using mixed LOCF. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Period 2 baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Subjects Who Achieved at Least 50% Improvement From Baseline in Disease Activity According to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) :Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||
End point description |
50% improvement from baseline in BASDAI: percentage of subjects achieved 50% decrease from baseline in BASDAI total score. BASDAI: 6 questions (Q) related to disease activity. Each of first 5 questions was scored by subject on 100 mm scale, range 0=none to 100=very severe, higher scores = more severe disease activity. Sixth question: duration of morning stiffness, was on scale for 0=0 hours to 100=2 hours, higher scores = larger duration of morning stiffness. BASDAI score obtained by computing mean score for 2 questions related to morning stiffness (Q5 [severity of morning stiffness], Q6 [duration of morning stiffness]) and adding that value to sum of scores for first 4Q and then dividing total by 5. Improvement was relative to baseline. FAS Period 3 was analyzed. Missing data was imputed using mixed LOCF. “n” = subjects evaluable at specific time points.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Period 3 baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Mean Change From Baseline in Highly Sensitive C Reactive Protein (hsCRP): Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
Change from baseline in hsCRP levels were reported. hsCRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Highly Sensitive C Reactive Protein (hsCRP): Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
Change from baseline in hsCRP levels were reported. hsCRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Highly Sensitive C Reactive Protein (hsCRP): Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
Change from baseline in hsCRP levels were reported. hsCRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Mean Change From Baseline in Highly Sensitive C Reactive Protein (hsCRP): Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
Change from baseline in hsCRP levels were reported. hsCRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Highly Sensitive C Reactive Protein (hsCRP): Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
Change from baseline in hsCRP levels were reported. hsCRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Mean Change From Baseline in Highly Sensitive C Reactive Protein (hsCRP): Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
Change from baseline in hsCRP levels were reported. hsCRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) VAS score > 82 at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||||
End point description |
The EQ-5D questionnaire is a health-related quality of life assessment (HRQOL). The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a VAS with response options. Overall EQ 5D VAS score ranged from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. In this outcome measure, data for percentage of subjects who reached the cut-off value of <82 is reported. This threshold was based on subject’s demographic characteristics and population norm. This outcome measure was planned to be analysed at baseline, Week 12 and 24. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) VAS score > 82 at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||
End point description |
The EQ-5D questionnaire is a HRQOL. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a VAS with response options. Overall EQ 5D VAS score ranged from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. In this outcome measure, data for percentage of subjects who reached the cut-off value of <82 is reported. This threshold was based on subject’s demographic characteristics and population norm. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Week 32, 48, 64
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) VAS score > 82 at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||
End point description |
The EQ-5D questionnaire is a HRQOL. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a VAS with response options. Overall EQ 5D VAS score ranged from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. In this outcome measure, data for percentage of subjects who reached the cut-off value of <82 is reported. This threshold was based on subject’s demographic characteristics and population norm. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 64, 76
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) VAS score > 82 at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||
End point description |
The EQ-5D questionnaire is a HRQOL. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a VAS with response options. Overall EQ 5D VAS score ranged from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. In this outcome measure, data for percentage of subjects who reached the cut-off value of <82 is reported. This threshold was based on subject’s demographic characteristics and population norm. This outcome measure was planned to be analyzed at baseline, Week 12 and 24. Missing data was imputed using mixed LOCF. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) VAS score > 82 at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||
End point description |
The EQ-5D questionnaire is a HRQOL. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a VAS with response options. Overall EQ 5D VAS score ranged from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. In this outcome measure, data for percentage of subjects who reached the cut-off value of <82 is reported. This threshold was based on subject’s demographic characteristics and population norm. This outcome measure was planned to be analyzed at baseline, Week 12 and 24. Missing data was imputed using mixed LOCF. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Week 32, 48, 64
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) VAS score > 82 at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||
End point description |
The EQ-5D questionnaire is a HRQOL. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a VAS with response options. Overall EQ 5D VAS score ranged from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. In this outcome measure, data for percentage of subjects who reached the cut-off value of <82 is reported. This threshold was based on subject’s demographic characteristics and population norm. This outcome measure was planned to be analyzed at baseline, Week 12 and 24. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 64, 76
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=0.05 Increase from Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index Score at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. This outcome measure was planned to be analyzed at baseline, Week 12 and 24.Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 12, 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects With >=0.05 Increase from Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index Score at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Week 32, 48, 64
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=0.05 Increase from Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index score at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 64, 76
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=0.05 Increase from Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index score at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. This outcome measure was planned to be analyzed at baseline, Week 12 and 24. Missing data was imputed using mixed LOCF. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 12, 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects With >=0.05 Increase from Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index score at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Missing data was imputed using mixed LOCF. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Week 32, 48, 64
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=0.05 Increase from Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index score at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 64, 76
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Score of 1 at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||||||||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. This outcome measure was planned to be
analyzed at baseline, Week 12 and 24. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Score of 1 at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||
End point timeframe |
Week 32, 48, 64
|
||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Score of 1 at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||
End point timeframe |
Week 64, 76
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Score of 1 at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. This outcome measure was planned to be analyzed at baseline, Week 12 and 24. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Score of 1 at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||
End point timeframe |
Week 32, 48, 64
|
||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||
End point title |
Percentage of Subjects Who Achieved an European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Score of 1 at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’ Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||
End point timeframe |
Week 64, 76
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index Scores at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index Scores at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index Scores at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index Scores at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index Scores at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index Scores at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||
End point description |
The EuroQol-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=severe problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "no problem" and 0 representing ‘’worst health condition’’. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Physical Component Score (PCS) at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health & functional status. SF-36 consists of 36 questions that grouped into 8 domains(physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health).Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status.Scores of 8 health aspects were summarized to derive 2 component scores (PCS; mental component scores [MCS]). Four domains of the SF-36 comprises PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of MCS score (vitality, social functioning, role-emotional, and mental health). Each PCS and MCS are scored from 0 to 100 with higher scores indicating better health. FAS Period 1: all subjects who took study medication and had one evaluation after baseline.“n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Physical Component Score (PCS) at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health & functional status. SF-36 consists of 36 questions that grouped into 8 domains(physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health).Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores (PCS and MCS). Four domains of the SF-36 comprises PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of MCS score (vitality, social functioning, role-emotional, and mental health). Each PCS and MCS are scored from 0 to 100 with higher scores indicating better health. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Physical Component Score (PCS) at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||||||||||||
End point description |
SF-36:used generic quality of life instrument that assesses subject’s general health & functional status. SF-36 consists of 36 questions that grouped into 8 domains(physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health).Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores (PCS and MCS). Four domains of the SF-36 comprises PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of MCS score (vitality, social functioning, role-emotional, and mental health). Each PCS and MCS are scored from 0 to 100 with higher scores indicating better health. FAS Period 3 included all subjects who took study retreatment medication and had at least 1 evaluation after restarting active therapy. “n”=subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Physical Component Score (PCS) Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health & functional status. SF-36 consists of 36 questions that grouped into 8 domains(physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health).Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status.Scores of 8 health aspects were summarized to derive 2 component scores (PCS and MCS).Four domains of the SF-36 comprises PCS score (physical functioning, role-physical, bodily pain, and general health) & remaining 4 domains comprises of MCS score (vitality, social functioning, role-emotional, and mental health). Each PCS and MCS scored from 0 to 100 with higher scores indicating better health. Missing data was imputed using mixed LOCF. FAS Period 1 included all subjects who took study medication and had one evaluation after baseline.“n”=subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Physical Component Score (PCS) at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health & functional status. SF-36 consists of 36 questions that grouped into 8 domains(physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health).Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores (PCS and MCS).Four domains of the SF-36 comprises PCS score (physical functioning, role-physical, bodily pain, and general health) & remaining 4 domains comprises of MCS score (vitality, social functioning, role-emotional, and mental health). Each PCS and MCS scored from 0 to 100 with higher scores indicating better health. FAS Period 2: all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Physical Component Score (PCS) at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health & functional status. SF-36 consists of 36 questions that grouped into 8 domains(physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health).Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores. Four domains of the SF-36 comprises PCS score (physical functioning, role-physical, bodily pain, and general health) & remaining 4 domains comprises of MCS score (vitality, social functioning, role-emotional, and mental health). Each PCS and MCS scored from 0 to 100 with higher scores indicating better health. FAS Period 3 population was analysed. Missing data was imputed using mixed LOCF. Here, “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=2.5 Improvement From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||
End point description |
SF-36 is widely used generic quality of life instrument that assesses the subject’s general health and functional status. SF-36 consists of 36 questions that grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive the 2 component scores: PCS, MCS. Four domains of the SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). The improvement was relative to baseline (Day 1). Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects With >=2.5 Improvement From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||
End point description |
SF-36 widely used generic quality of life instrument that assesses the subject’s general health and functional status. SF-36 consists of 36 questions that grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive the 2 component scores: PCS, MCS. Four domains of the SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). Improvement was relative to period 2 baseline (last visit before treatment withdrawal). Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” = subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Period 2 baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=2.5 Improvement From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses the subject’s general health and functional status. SF-36 consists of 36 questions that grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive the 2 component scores: PCS, MCS. Four domains of the SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). Improvement was relative to period 3 baseline (last visit before retreatment). FAS Period 3 population was analysed. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Period 3 baseline (last visit before retreatment), Week 64, 76
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=5 Improvement From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses the subject’s general health and functional status. SF-36 consists of 36 questions that grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive the 2 component scores: PCS, MCS. Four domains of the SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health. Improvement was relative to baseline (Day 1). Missing data was imputed using mixed LOCF. FAS Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects With >=5 Improvement From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses the subject’s general health and functional status. SF-36 consists of 36 questions that grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive the 2 component scores: PCS, MCS. Four domains of the SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health. Improvement was relative to period 2 baseline(last visit before treatment withdrawal). FAS Period 2: all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. “n”= subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Period 2 baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=5 Improvement From Baseline in Short Form-36 (SF-36) Physical Component Score at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses the subject’s general health and functional status. SF-36 consists of 36 questions that grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive the 2 component scores: PCS, MCS. Four domains of the SF-36 comprises the PCS score and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health. Improvement was relative to period 3 baseline (last visit before retreatment). FAS Period 3: all subjects who took study retreatment medication and had at least 1 evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. “n” = subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Period 3 baseline (last visit before retreatment), Week 64, 76
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses the subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive the 2 component scores: PCS, MCS. Four domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). Each PCS and MCS are scored from 0 to 100 with higher scores indicating better health (0= worst value and 100= best value). FAS Period 1: all subjects who took study medication and had 1 evaluation after baseline.“n” = subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses the subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive the 2 component scores: PCS, MCS. Four domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). Each PCS and MCS are scored from 0 to 100 with higher scores indicating better health (0= worst value and 100= best value). FAS Period 2: all subjects who had at least 1 evaluation during period 2. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores: PCS, MCS. Four domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health. FAS Period 3: all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores: PCS, MCS. Four domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health. FAS Period 1: all subjects who took study medication and had 1 evaluation after baseline. Missing data was imputed using mixed LOCF. “n” = subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores: PCS, MCS. Four domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores: PCS, MCS. Four domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health. FAS Period 3 population was analysed. Missing data was imputed using mixed LOCF. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=2.5 Improvement From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores: PCS, MCS. Four domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health. Improvement was relative to baseline (Day 1). FAS Period 1: all subjects who took study medication and had 1 evaluation after baseline. Here, “n” = subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects With >=2.5 Improvement From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores: PCS, MCS. Four domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health. FAS for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Period 2 baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=2.5 Improvement From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||
End point description |
SF-36: used generic quality of life instrument that assesses subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive 2 component scores: PCS, MCS. Four domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health. FAS Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” = subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Period 3 baseline (last visit before retreatment), Week 64, 76
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=5 Improvement From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||
End point description |
SF-36 is widely used generic quality of life instrument that assesses subject’s general health and functional status. SF-36 consists 36 questions that grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects summarized to derive he 2 component scores: PCS, MCS. 4 domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of MCS score (vitality, social functioning, role-emotional, and mental health). PCS and MCS are scored from 0 to 100 with higher scores indicating better health. Improvement was relative to baseline (Day 1). FAS Period 1:all subjects who took study medication and had one evaluation after baseline.“n” = subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Percentage of Subjects With >=5 Improvement From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 32, 48, 64: Observed Cases (OC):Period 2 | ||||||||||||||
End point description |
SF-36 is widely used generic quality of life instrument that assesses subject’s general health and functional status. It consists 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects summarized to derive he 2 component scores: PCS, MCS. 4 domains of SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of MCS score (vitality, social functioning, role-emotional, and mental health). Each PCS and MCS are scored from 0 to 100 with higher scores indicating better health. Improvement was relative to period 2 baseline. FAS Period 2: all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Period 2 baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With >=5 Improvement From Baseline in Short Form-36 (SF-36) Mental Component Score (MCS) at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||
End point description |
SF-36 : generic quality of life instrument that assesses subject’s general health and functional status. It consists of 36 questions grouped into 8 domains (physical functioning, vitality, social functioning, mental health, role physical, bodily pain, role emotional and general health). Domain scores range from 0 (worst value) to 100 (best value), with greater scores reflecting better health status. Scores of 8 health aspects were summarized to derive the 2 component scores: PCS, MCS. Four domains of the SF-36 comprises the PCS score (physical functioning, role-physical, bodily pain, and general health) and remaining 4 domains comprises of the MCS score (vitality, social functioning, role-emotional, and mental health). Improvement was relative to period 3 baseline. FAS Period 3: all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Period 3 baseline (last visit before retreatment), Week 64, 76
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess degree to which a specified health problem here "AS" affected work attendance, work productivity and productivity in non-work regular activities. Subjects were asked to consider past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected work productivity, and degree to a which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, and percent non-work activity impairment due to AS. Computed range for each sub-scale was from 0-100, with higher numbers indicating greater impairment and less productivity. FAS Period 1 was analysed. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess degree to which a specified health problem here "AS" affected work attendance, work productivity and productivity in non-work regular activities. Subjects were asked to consider past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected work productivity, and degree to a which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, and percent non-work activity impairment due to AS. Computed range for each sub-scale was from 0-100, with higher numbers indicating greater impairment and less productivity. FAS Period 2 was analysed. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess degree to which a specified health problem here "AS" affected work attendance, work productivity and productivity in non-work regular activities. Subjects were asked to consider past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected work productivity, and degree to a which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, and percent non-work activity impairment due to AS. Computed range for each sub-scale was from 0-100, with higher numbers indicating greater impairment and less productivity. FAS Period 3 was analysed. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
WPAI assesses work productivity and impairment.6-item questionnaire used to assess degree to which a specified health problem here "AS" affected work attendance, WP and productivity in non-work regular activities. Subjects were asked to consider past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected work productivity, degree to a which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, and percent non-work activity impairment due to AS. Computed range for each sub-scale was from 0-100,higher numbers indicating greater impairment and less productivity. Missing data was imputed using mixed LOCF.FAS Period 1 was analysed. “n”=subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
WPAI assesses work productivity and impairment.6-item questionnaire used to assess degree to which a specified health problem here "AS" affected work attendance, WP and productivity in non-work regular activities. Subjects were asked to consider past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected work productivity, degree to a which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, and percent non-work activity impairment due to AS. Computed range for each sub-scale was from 0-100,higher numbers indicating greater impairment and less productivity. Missing data was imputed using mixed LOCF.FAS Period 2 was analysed. “n”=subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Work Productivity and Activity Impairment (WPAI): Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
WPAI assesses work productivity and impairment.6-item questionnaire used to assess degree to which a specified health problem here "AS" affected work attendance, WP and productivity in non-work regular activities. Subjects were asked to consider past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected work productivity, degree to a which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, and percent non-work activity impairment due to AS. Computed range for each sub-scale was from 0-100,higher numbers indicating greater impairment and less productivity. Missing data was imputed using mixed LOCF.FAS Period 3 was analysed. “n”=subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score) at Week 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||
End point description |
Change from baseline in MRI score of spine was assessed using SPARCC method. Scoring was based on 6 consecutive coronal slices from posterior to anterior. Each joint was divided into 4 quadrants. Each quadrant was assigned score of 0=no lesion or 1=increased signal. This part of coring allows for total score ranging from 0-8 for 2 joints of one coronal slice. For each slice, score was increased by 1 for each joint that exhibits an intense signal in any quadrant (thereby allowing for an increase of up to 2 points in total score for each slice). Also, for each slice, an additional score of 1 was given for each joint that includes a lesion demonstrating continuous increased signal of depth >=1 cm from articular surface (thereby allowing for an additional increase of up to 2 points for each slice). FAS Period 1: all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF.“n” = subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score) at Week 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||
End point description |
Change from baseline in MRI score of spine was assessed using SPARCC method. Scoring was based on 6 consecutive coronal slices from posterior to anterior. Each joint was divided into 4 quadrants. Each quadrant was assigned score of 0=no lesion or 1=increased signal. This part of coring allows for total score ranging from 0-8 for 2 joints of one coronal slice. For each slice, score was increased by 1 for each joint that exhibits an intense signal in any quadrant (thereby allowing for an increase of up to 2 points in total score for each slice). Also, for each slice, an additional score of 1 was given for each joint that includes a lesion demonstrating continuous increased signal of depth >=1 cm from articular surface. Total minimum and maximum score for all joints across 6 slices was 0 to 72 where higher scores reflecting worse disease. FAS Period 2 was analysed. Missing data was imputed using mixed LOCF. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 48, 64
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score) at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||
End point description |
Change from baseline in MRI score of spine was assessed using SPARCC method. Scoring was based on 6 consecutive coronal slices from posterior to anterior. Each joint was divided into 4 quadrants. Each quadrant was assigned score of 0=no lesion or 1=increased signal. This part of coring allows for total score ranging from 0-8 for 2 joints of one coronal slice. For each slice, score was increased by 1 for each joint that exhibits an intense signal in any quadrant (thereby allowing for an increase of up to 2 points in total score for each slice). Also, for each slice, an additional score of 1 was given for each joint that includes a lesion demonstrating continuous increased signal of depth >=1 cm from articular surface. Total minimum and maximum score for all joints across 6 slices was 0 to 72 where higher scores reflecting worse disease. FAS Period 3 was analysed. Missing data was imputed using mixed LOCF. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score) at Week 24: Observed Cases (OC): Period 1 | ||||||||||||
End point description |
Change from baseline in MRI score of spine assessed using SPARCC. Scoring based on 6 consecutive coronal slices from posterior to anterior. Each joint was divided into 4 quadrants. Each quadrant was assigned score of 0=no lesion or 1=increased signal. This part of coring allows for total score ranging from 0-8 for 2 joints of one coronal slice. For each slice, score was increased by 1 for each joint that exhibits an intense signal in any quadrant (thereby allowing for an increase of up to 2 points in total score for each slice). Also, for each slice, an additional score of 1 was given for each joint that includes a lesion demonstrating continuous increased signal of depth >=1 cm from articular surface. Total minimum and maximum score for all joints across 6 slices was 0 to 72 where higher scores reflecting worse disease. FAS Period 1: all subjects who took study medication and had 1 evaluation after baseline. “n” = subjects evaluable at specific time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score) at Week 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||
End point description |
Change from baseline in MRI score of spine assessed using SPARCC. Scoring based on 6 consecutive coronal slices from posterior to anterior. Each joint was divided into 4 quadrants. Each quadrant was assigned score of 0=no lesion or 1=increased signal. This part of coring allows for total score ranging from 0-8 for 2 joints of one coronal slice. For each slice, score was increased by 1 for each joint that exhibits an intense signal in any quadrant (thereby allowing for an increase of up to 2 points in total score for each slice). Also, for each slice, an additional score of 1 was given for each joint that includes a lesion demonstrating continuous increased signal of depth >=1 cm from articular surface. Total minimum and maximum score for all joints across 6 slices was 0 to 72 where higher scores reflecting worse disease. FAS Period 2 :all subjects who had at least one evaluation during period 2. “n” = subjects evaluable at specific time points.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 48, 64
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score) at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||||||||||||
End point description |
Change from baseline in MRI score of spine assessed using SPARCC. Scoring based on 6 consecutive coronal slices from posterior to anterior. Each joint was divided into 4 quadrants. Each quadrant was assigned score of 0=no lesion or 1=increased signal. This part of coring allows for total score ranging from 0-8 for 2 joints of one coronal slice. For each slice, score was increased by 1 for each joint that exhibits an intense signal in any quadrant (thereby allowing for an increase of up to 2 points in total score for each slice). Also, for each slice, an additional score of 1 was given for each joint that includes a lesion demonstrating continuous increased signal of depth >=1 cm from articular surface. Total minimum and maximum score for all joints across 6 slices was 0 to 72 where higher scores reflecting worse disease. FAS Period 3 population was analysed. Here, “n” = subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Time to Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease After Re-treatment in Period 3 | ||||||||
End point description |
Time to ASDAS inactive disease was defined as the time from first dose of retreatment until the first observed event of ASDAS inactive disease. Inactive disease is defined as an ASDAS score <1.3. for ASDAS-CRP or ASDAS score of >=2.1 for ASDAS-ESR. Subjects who did not achieve ASDAS inactive disease were censored at the time of the last ASDAS evaluation in the interval. The full analysis set for retreatment period included all subjects who took study retreatment medication and had at least 1 evaluation after restarting active therapy.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Within 12 weeks of Period 3 (retreatment period from Week 64 to 76)
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Subject Assessment of Disease Activity (SADA) Visual Analogue Scale (VAS): Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
Subjects assessed their overall disease activity over the last 48 hours by using a 100 mm pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Subject Assessment of Disease Activity (SADA) Visual Analogue Scale (VAS): Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their overall disease activity over the last 48 hours by using a 100 mm pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Subject Assessment of Disease Activity (SADA) Visual Analogue Scale (VAS): Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their overall disease activity over the last 48 hours by using a 100 mm pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Subject Assessment of Disease Activity (SADA) Visual Analogue Scale (VAS): Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
Subjects assessed their overall disease activity over the last 48 hours by using a 100 mm pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Subject Assessment of Disease Activity (SADA) Visual Analogue Scale (VAS): Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their overall disease activity over the last 48 hours by using a 100 mm pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Subject Assessment of Disease Activity (SADA) Visual Analogue Scale (VAS): Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
Subjects assessed their overall disease activity over the last 48 hours by using a 100 mm pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Physician Global Assessment (PGA) Visual Analogue Scale (VAS): Observed Cases (OC): Period 1 | ||||||||||||||||||||
End point description |
The physician assessed the overall disease activity of subjects over the last 48 hours by using a 100 mm VAS pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Physician Global Assessment (PGA) Visual Analogue Scale (VAS): Observed Cases (OC): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
The physician assessed the overall disease activity of subjects over the last 48 hours by using a 100 mm VAS pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Physician Global Assessment (PGA) Visual Analogue Scale (VAS): Observed Cases (OC): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
The physician assessed the overall disease activity of subjects over the last 48 hours by using a 100 mm VAS pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Change From Baseline in Physician Global Assessment (PGA) Visual Analogue Scale (VAS): Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||||||||
End point description |
The physician assessed the overall disease activity of subjects over the last 48 hours by using a 100 mm VAS pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 4, 8, 12, 16, 24
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Physician Global Assessment (PGA) Visual Analogue Scale (VAS): Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||||||||||||||
End point description |
The physician assessed the overall disease activity of subjects over the last 48 hours by using a 100 mm VAS pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 28, 32, 40, 48, 56, 64
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
End point title |
Change From Baseline in Physician Global Assessment (PGA) Visual Analogue Scale (VAS): Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||||||||||||||
End point description |
The physician assessed the overall disease activity of subjects over the last 48 hours by using a 100 mm VAS pain scale that ranges from 0 mm (none) to 100 mm (severe pain), where higher scores indicated more pain. The reported values then converted to cm for analysis purposes. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 68, 72, 76
|
||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Bath Ankylosing Spondylitis Global Index (BAS-G) Score at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||
End point description |
The BAS-G was a 2-question assessment evaluating the effect of AS on the subject’s wellbeing over the last week and last 6 months. Each question scored by the subject on a 100 mm VAS scale ranging from 0 (very Good) to 100 (very Bad), where higher scores indicated worse health condition. The total BAS-G score calculated as the average scores of these two questions and then converted into cm for analysis. Total BAS-G score ranged from 0 to 10 cm, where higher scores indicated worse health condition. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Bath Ankylosing Spondylitis Global Index (BAS-G) Score) at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||
End point description |
The BAS-G was a 2-question assessment evaluating the effect of AS on the subject’s wellbeing over the last week and last 6 months. Each question scored by the subject on a 100 mm VAS scale ranging from 0 (very Good) to 100 (very Bad), where higher scores indicated worse health condition. The total BAS-G score calculated as the average scores of these two questions and then converted into cm for analysis. Total BAS-G score ranged from 0 to 10 cm, where higher scores indicated worse health condition. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Bath Ankylosing Spondylitis Global Index (BAS-G) Score at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||
End point description |
The BAS-G was a 2-question assessment evaluating the effect of AS on the subject’s wellbeing over the last week and last 6 months. Each question scored by the subject on a 100 mm VAS scale ranging from 0 (very Good) to 100 (very Bad), where higher scores indicated worse health condition. The total BAS-G score calculated as the average scores of these two questions and then converted into cm for analysis. Total BAS-G score ranged from 0 to 10 cm, where higher scores indicated worse health condition. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Bath Ankylosing Spondylitis Global Index (BAS-G) Score at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||||
End point description |
The BAS-G was a 2-question assessment evaluating the effect of AS on the subject’s wellbeing over the last week and last 6 months. Each question scored by the subject on a 100 mm VAS scale ranging from 0 (very Good) to 100 (very Bad), where higher scores indicated worse health condition. The total BAS-G score calculated as the average scores of these two questions and then converted into cm for analysis. Total BAS-G score ranged from 0 to 10 cm, where higher scores indicated worse health condition. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Bath Ankylosing Spondylitis Global Index (BAS-G) Score) at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||||||
End point description |
The BAS-G was a 2-question assessment evaluating the effect of AS on the subject’s wellbeing over the last week and last 6 months. Each question scored by the subject on a 100 mm VAS scale ranging from 0 (very Good) to 100 (very Bad), where higher scores indicated worse health condition. The total BAS-G score calculated as the average scores of these two questions and then converted into cm for analysis. Total BAS-G score ranged from 0 to 10 cm, where higher scores indicated worse health condition. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Bath Ankylosing Spondylitis Global Index (BAS-G) Score at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||||||||||||
End point description |
The BAS-G was a 2-question assessment evaluating the effect of AS on the subject’s wellbeing over the last week and last 6 months. Each question scored by the subject on a 100 mm VAS scale ranging from 0 (very Good) to 100 (very Bad), where higher scores indicated worse health condition. The total BAS-G score calculated as the average scores of these two questions and then converted into cm for analysis. Total BAS-G score ranged from 0 to 10 cm, where higher scores indicated worse health condition. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Number of Swollen Joint Count at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||||
End point description |
Number of swollen joints was determined by examination of 44 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling =0, swelling =1. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Number of Swollen Joint Count at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||||||
End point description |
Number of swollen joints was determined by examination of 44 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling =0, swelling =1. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Number of Swollen Joint Count at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||||||||||||
End point description |
Number of swollen joints was determined by examination of 44 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling =0, swelling =1. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Number of Swollen Joint Count at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||
End point description |
Number of swollen joints was determined by examination of 44 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling =0, swelling =1. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Number of Swollen Joint Count at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||
End point description |
Number of swollen joints was determined by examination of 44 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling =0, swelling =1. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Number of Swollen Joint Count at Week 64, 76 : Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||
End point description |
Number of swollen joints was determined by examination of 44 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling =0, swelling =1. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Number of Tender Joint Count at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||||
End point description |
Number of tender joints was determined by examining 44 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Number of Tender Joint Count at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||||||
End point description |
Number of tender joints was determined by examining 44 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Number of Tender Joint Count at Week 64, 76: : Observed Cases (OC): Period 3 | ||||||||||||||||||||||
End point description |
Number of tender joints was determined by examining 44 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Number of Tender Joint Count at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||
End point description |
Number of tender joints was determined by examining 44 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Number of Tender Joint Count at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||
End point description |
Number of tender joints was determined by examining 44 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Number of Tender Joint Count at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||
End point description |
Number of tender joints was determined by examining 44 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Dactylitis Total Score at Week 12, 24: Observed Cases (OC): Period 1 | ||||||||||||||
End point description |
Dactylitis is the inflammation of finger and/or toe joints (digits). Dactylitis scores was calculated by evaluating each of the 10 fingers and 10 toes. Each digit was evaluated on a 4-point scale ranging from of 0 to 3 where 0 = none, 1= mild, 2 = moderate, 3 = severe inflammation. The total score was calculated as the sum of scores for the 20 digits, total score ranged from 0 to 60, where higher scores indicated severe inflammation. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Dactylitis Total Score at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||||||
End point description |
Dactylitis is the inflammation of finger and/or toe joints (digits). Dactylitis scores was calculated by evaluating each of the 10 fingers and 10 toes. Each digit was evaluated on a 4-point scale ranging from of 0 to 3 where 0 = none, 1= mild, 2 = moderate, 3 = severe inflammation. The total score was calculated as the sum of scores for the 20 digits, total score ranged from 0 to 60, where higher scores indicated severe inflammation. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Dactylitis Total Score at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||||||||||||
End point description |
Dactylitis is the inflammation of finger and/or toe joints (digits). Dactylitis scores was calculated by evaluating each of the 10 fingers and 10 toes. Each digit was evaluated on a 4-point scale ranging from of 0 to 3 where 0 = none, 1= mild, 2 = moderate, 3 = severe inflammation. The total score was calculated as the sum of scores for the 20 digits, total score ranged from 0 to 60, where higher scores indicated severe inflammation. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Dactylitis Total Score at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||
End point description |
Dactylitis is the inflammation of finger and/or toe joints (digits). Dactylitis scores was calculated by evaluating each of the 10 fingers and 10 toes. Each digit was evaluated on a 4-point scale ranging from of 0 to 3 where 0 = none, 1= mild, 2 = moderate, 3 = severe inflammation. The total score was calculated as the sum of scores for the 20 digits, total score ranged from 0 to 60, where higher scores indicated severe inflammation. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Dactylitis Total Score at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||
End point description |
Dactylitis is the inflammation of finger and/or toe joints (digits). Dactylitis scores was calculated by evaluating each of the 10 fingers and 10 toes. Each digit was evaluated on a 4-point scale ranging from of 0 to 3 where 0 = none, 1= mild, 2 = moderate, 3 = severe inflammation. The total score was calculated as the sum of scores for the 20 digits, total score ranged from 0 to 60, where higher scores indicated severe inflammation. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Dactylitis Total Score at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||
End point description |
Dactylitis is the inflammation of finger and/or toe joints (digits). Dactylitis scores was calculated by evaluating each of the 10 fingers and 10 toes. Each digit was evaluated on a 4-point scale ranging from of 0 to 3 where 0 = none, 1= mild, 2 = moderate, 3 = severe inflammation. The total score was calculated as the sum of scores for the 20 digits, total score ranged from 0 to 60, where higher scores indicated severe inflammation. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2 Baseline (last visit before treatment withdrawal), Period 3 Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 12, 24: Observed Cases (OC) : Period 1 | ||||||||||||||
End point description |
The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Each site is scored as 0 or 1 depending on whether enthesitis is present or absent. Sites assessed include 1st costochondral joint (left/right), 7 th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. The MASES is the sum of all site scores range from 0 (no inflammation) to 13 (worst possible inflammation) where higher scores indicate more severe inflammation of entheses. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 32, 48, 64: Observed Cases (OC): Period 2 | ||||||||||||||||||||||
End point description |
The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Each site is scored as 0 or 1 depending on whether enthesitis is present or absent. Sites assessed include 1st costochondral joint (left/right), 7 th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. The MASES is the sum of all site scores range from 0 (no inflammation) to 13 (worst possible inflammation) where higher scores indicate more severe inflammation of entheses. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 64, 76: Observed Cases (OC): Period 3 | ||||||||||||||||||||||
End point description |
The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Each site is scored as 0 or 1 depending on whether enthesitis is present or absent. Sites assessed include 1st costochondral joint (left/right), 7 th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. The MASES is the sum of all site scores range from 0 (no inflammation) to 13 (worst possible inflammation) where higher scores indicate more severe inflammation of entheses. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 12, 24: Last Observation Carried Forward (LOCF): Period 1 | ||||||||||||||
End point description |
The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Each site is scored as 0 or 1 depending on whether enthesitis is present or absent. Sites assessed include 1st costochondral joint (left/right), 7 th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. The MASES is the sum of all site scores range from 0 (no inflammation) to 13 (worst possible inflammation) where higher scores indicate more severe inflammation of entheses. Full analysis set for Period 1 included all subjects who took study medication and had one evaluation after baseline. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Baseline (Day 1 Week 1), Week 12, 24
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 32, 48, 64: Last Observation Carried Forward (LOCF): Period 2 | ||||||||||||||||||||||
End point description |
The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Each site is scored as 0 or 1 depending on whether enthesitis is present or absent. Sites assessed include 1st costochondral joint (left/right), 7 th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. The MASES is the sum of all site scores range from 0 (no inflammation) to 13 (worst possible inflammation) where higher scores indicate more severe inflammation of entheses. Full analysis set for Period 2 included all subjects who had at least one evaluation during period 2. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Week 32, 48, 64
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 64, 76: Last Observation Carried Forward (LOCF): Period 3 | ||||||||||||||||||||||
End point description |
The MASES is an index used to measure the severity of enthesitis. Enthesitis is the inflammation of enthuses (heels). The MASES assesses 13 sites for enthesitis. Each site is scored as 0 or 1 depending on whether enthesitis is present or absent. Sites assessed include 1st costochondral joint (left/right), 7 th costochondral joint (l/r), posterior superior iliac spine (l/r), posterior anterior iliac spine (l/r), iliac crest (l/r), proximal insertion of Achilles tendon (l/r) and 5th lumbar spinous process. The MASES is the sum of all site scores range from 0 (no inflammation) to 13 (worst possible inflammation) where higher scores indicate more severe inflammation of entheses. Full analysis set for Period 3 included all subjects who took study retreatment medication and had at least one evaluation after restarting active therapy. Missing data was imputed using mixed LOCF. Here, “n” signifies subjects evaluable at specific time points.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Period 1 Baseline (Day 1 Week 1), Period 2: Baseline (last visit before treatment withdrawal), Period 3: Baseline (last visit before retreatment), Week 64, 76
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Number of Subjects With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | ||||||||||||||||||||
End point description |
An AE was any untoward medical occurrence in a subject who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Baseline (Day 1) up to 28 days after last dose of study drug (for period 1: maximum up to 28 weeks, for period 2: maximum up to 68 weeks, period 3: maximum up to 80 weeks)
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Baseline (Day 1) up to 28 days after last dose of study drug (for period 1: maximum up to 28 weeks, for period 2: maximum up to 68 weeks, period 3: maximum up to 80 weeks)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Same event may appear as AE and SAE, what is presented are distinct events. Event may be categorized as serious in 1 subject and as non-serious in another subject or 1 subject may have experienced both serious and non-serious event during study.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Etanercept: Period 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All enrolled subjects with nr-ax SpA were treated for 24 weeks with 50 milligram weekly dose of Etanercept in Period 1 (Induction Period). Subjects who did not qualify for Period 2 were followed up until 28 days after last dose of Etanercept. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Etanercept: Period 3
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who achieved an ASDAS ESR level >= 2.1 by Week 64, then entered into Period 3 (Retreatment Period) of 12 weeks, treated with 50 mg weekly doses, and then followed up until 28 days after last dose of Etanercept. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Etanercept: Period 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who achieved ASDAS CRP less than 1.3 at Week 24 then entered into Period 2 (Withdrawal Period). In this period, subjects discontinued Etanercept for 40 weeks (from Week 24 to Week 64). Subjects who did not qualify for Period 2 were followed up until 28 days after last dose of Etanercept. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |